Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.

von Arx LB, Rachman J, Webb J, Casey C, Patel A, Diomatari C, Wood R, Idris I

Diabetes, obesity & metabolism10 Feb 2023Cited by 6 (Europe PMC)

PMID36692268DOI10.1111/dom.14985PepBankPUB-36692268

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studyOther
In adults with type 2 diabetes on dulaglutide 0.75 mg, 75.0% had HbA1c at least 7.5% at 6 to 9 months.
In plain wordsIn patients on low-dose dulaglutide, many still had high HbA1c during follow-up.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHbA1c above target during treatment
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mgAs given in this study (human).
Measurements
Proportion with HbA1c ≥7.5%
75%
dulaglutide 0.75 mg, 6 to 9 months
Source sentences
Summary
At 6 to 9 months, 75.0% of those on dulaglutide 0.75 mg and 57.6% of those on semaglutide 0.25 mg or 0.5 mg had an HbA1c level ≥7.5% (≥58.46 mmol/mol).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D who received their first primary care prescription of dulaglutide or semaglutide between January and July 2019 were identified from the UK Clinical Practice Research Datalink GOLD primary care database. Doses prescribed, glycated haemoglobin (HbA1c), body mass index (BMI) and concomi…
Report a problemFND-3669226803
02HumanObservational studyOther
In adults with type 2 diabetes on semaglutide 0.25 mg or 0.5 mg, 57.6% had HbA1c at least 7.5% at 6 to 9 months.
In plain wordsIn patients on low-dose semaglutide, many still had high HbA1c during follow-up.
Peptide
Semaglutide
Outcome
Not applicableHbA1c above target during treatment
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.25 mg or 0.5 mgAs given in this study (human).
Measurements
Proportion with HbA1c ≥7.5%
57.6%
semaglutide 0.25 mg or 0.5 mg, 6 to 9 months
Source sentences
Summary
At 6 to 9 months, 75.0% of those on dulaglutide 0.75 mg and 57.6% of those on semaglutide 0.25 mg or 0.5 mg had an HbA1c level ≥7.5% (≥58.46 mmol/mol).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D who received their first primary care prescription of dulaglutide or semaglutide between January and July 2019 were identified from the UK Clinical Practice Research Datalink GOLD primary care database. Doses prescribed, glycated haemoglobin (HbA1c), body mass index (BMI) and concomi…
Report a problemFND-3669226804

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients first prescribed dulaglutide, 93.0% had HbA1c at least 7.5%, and 56.4% had HbA1c at least 9.0%.
In plain wordsIn patients first prescribed dulaglutide, most had high HbA1c before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHbA1c at first prescription
Study
n = 748
Outcome group
Glycemic control · Metabolic and weight
Measurements
Patients with HbA1c ≥7.5%
93%
dulaglutide, first prescription
Patients with HbA1c ≥9.0%
56.4%
dulaglutide, first prescription
Source sentences
Summary
Of the patients prescribed dulaglutide (N = 748; mean [SD] age 59.0 [11.2] years) and semaglutide (N = 437; mean [SD] age 58.4 [10.6] years), 93.0% and 89.0%, respectively, had an HbA1c level ≥7.5% (≥58.46 mmol/mol), and 56.4% and 54.9%, respectively, had an HbA1c level ≥9.0% (≥74.86 mmol/mol), at first prescription.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D who received their first primary care prescription of dulaglutide or semaglutide between January and July 2019 were identified from the UK Clinical Practice Research Datalink GOLD primary care database. Doses prescribed, glycated haemoglobin (HbA1c), body mass index (BMI) and concomi…
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3669226801
04HumanNot a test of Semaglutide aloneObservational studyOther
In patients first prescribed semaglutide, 89.0% had HbA1c at least 7.5%, and 54.9% had HbA1c at least 9.0%.
In plain wordsIn patients first prescribed semaglutide, most had high HbA1c before treatment.
Peptide
Semaglutide
Outcome
Not applicableHbA1c at first prescription
Study
n = 437
Outcome group
Glycemic control · Metabolic and weight
Measurements
Patients with HbA1c ≥7.5%
89%
semaglutide, first prescription
Patients with HbA1c ≥9.0%
54.9%
semaglutide, first prescription
Source sentences
Summary
Of the patients prescribed dulaglutide (N = 748; mean [SD] age 59.0 [11.2] years) and semaglutide (N = 437; mean [SD] age 58.4 [10.6] years), 93.0% and 89.0%, respectively, had an HbA1c level ≥7.5% (≥58.46 mmol/mol), and 56.4% and 54.9%, respectively, had an HbA1c level ≥9.0% (≥74.86 mmol/mol), at first prescription.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D who received their first primary care prescription of dulaglutide or semaglutide between January and July 2019 were identified from the UK Clinical Practice Research Datalink GOLD primary care database. Doses prescribed, glycated haemoglobin (HbA1c), body mass index (BMI) and concomi…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3669226802
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
At 9 months, 21.9% of the dulaglutide cohort used the suboptimal dose of 0.75 mg.
In plain wordsIn patients prescribed dulaglutide, some still used a suboptimal dose at follow-up.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSuboptimal dose use
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Proportion on suboptimal dose
21.9%
dulaglutide cohort, 0.75 mg, 9 months
Source sentences
Summary
At 9 months, 21.9% of the dulaglutide cohort were on the suboptimal dose of 0.75 mg, and 46.1% of the semaglutide cohort were on the suboptimal doses of 0.25 mg or 0.5 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D who received their first primary care prescription of dulaglutide or semaglutide between January and July 2019 were identified from the UK Clinical Practice Research Datalink GOLD primary care database. Doses prescribed, glycated haemoglobin (HbA1c), body mass index (BMI) and concomi…
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3669226805
06HumanNot a test of Semaglutide aloneObservational studyOther
At 9 months, 46.1% of the semaglutide cohort used suboptimal doses of 0.25 mg or 0.5 mg.
In plain wordsIn patients prescribed semaglutide, many still used suboptimal doses at follow-up.
Peptide
Semaglutide
Outcome
Not applicableSuboptimal dose use
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Proportion on suboptimal doses
46.1%
semaglutide cohort, 0.25 mg or 0.5 mg, 9 months
Source sentences
Summary
At 9 months, 21.9% of the dulaglutide cohort were on the suboptimal dose of 0.75 mg, and 46.1% of the semaglutide cohort were on the suboptimal doses of 0.25 mg or 0.5 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D who received their first primary care prescription of dulaglutide or semaglutide between January and July 2019 were identified from the UK Clinical Practice Research Datalink GOLD primary care database. Doses prescribed, glycated haemoglobin (HbA1c), body mass index (BMI) and concomi…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3669226806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.